AURORA kinases are over-expressed in colon, prostate, breast, lung, pancreatic and other cancers. Drugs that inhibit AURORA kinases thus have potential therapeutic utility in the treatment of a wide range of cancers.

Ambit is currently conducting lead optimization on several sub-micromolar AURORA inhibitors that were identified using its kinase profiling platform. Additionally, Ambit is evaluating an AURORA inhibitor program licensed from Bristol-Myers Squibb in late 2005. Ambit plans to identify a clinical candidate from its AURORA programs in 2008.